Government Sets Up Panel to Review Pharma Marketing Rules in India

Government Forms Committee to Review Pharma Marketing Rules in India: What UCPMP Changes Could Mean for the Industry

India's pharmaceutical industry could see changes to its marketing oversight framework following a new government initiative to examine existing rules and recommend measures to address unethical promotional practices.

The Department of Pharmaceuticals, under the Ministry of Chemicals and Fertilizers, announced on 23 October 2026 that it had constituted a committee to comprehensively review the regulatory framework governing pharmaceutical marketing. The committee will examine existing monitoring and enforcement mechanisms and recommend ways to improve transparency, accountability and compliance. Press Information Bureau

The review places the spotlight on the Uniform Code for Pharmaceutical Marketing Practices (UCPMP), the framework governing ethical pharmaceutical promotion and interactions between pharmaceutical companies and healthcare professionals.

For pharmaceutical manufacturers, marketing teams, medical representatives and healthcare professionals, the outcome could be significant. However, the committee's formation does not itself introduce new marketing restrictions. Its task is to examine the current framework and recommend improvements to the government.

Who Will Lead the Pharmaceutical Marketing Review Committee?

According to the official announcement, the committee will be chaired by Dr. M. Srinivas, Member of NITI Aayog.

Its other members are:

• Preeti Sudan: Former Union Health Secretary.

• Dr. Naresh Trehan: Chairman and Managing Director of Medanta.

The committee has been asked to submit its recommendations within two months of its first meeting, following the necessary consultation process. The deadline is therefore linked to the date of that first meeting, not automatically to the announcement date. Press Information Bureau

The committee's mandate covers the effectiveness of existing oversight mechanisms, the need for stronger regulatory measures and the legal framework that might be appropriate to implement its recommendations.

It will also consult relevant stakeholders, technical experts, professional bodies and other institutions as considered necessary.

What Is UCPMP 2024?

The Uniform Code for Pharmaceutical Marketing Practices is intended to promote ethical marketing by pharmaceutical companies and establish appropriate standards for their interactions with healthcare professionals.

The original code was introduced in 2015. The Department of Pharmaceuticals subsequently introduced UCPMP 2024, replacing the earlier version and strengthening its implementation framework.

The 2024 code remains in operation. It was also amended in September 2025. Press Information Bureau

The framework addresses concerns surrounding pharmaceutical promotion, including the relationship between companies and healthcare professionals, marketing expenditure disclosures, complaint handling and compliance monitoring.

The government has previously highlighted several elements of UCPMP 2024, including:

• Ethics Committees for Pharmaceutical Marketing Practices.

• Appointment of ethics officers by pharmaceutical companies.

• A structured mechanism for handling complaints and appeals.

• Self-declarations relating to compliance.

• Disclosure of prescribed marketing expenditure.

• Rules governing promotional interactions with healthcare professionals and healthcare organisations. Press Information Bureau

These provisions are intended to encourage responsible promotion and reduce the risk of commercial incentives improperly influencing professional decisions.

Why Is the Government Reviewing the Existing Framework?

The latest announcement does not establish that every part of the current framework has failed. Instead, it confirms that the government wants a comprehensive examination of unethical pharmaceutical marketing and the mechanisms used to prevent it.

The committee will assess whether existing monitoring, oversight and enforcement arrangements are effective and identify areas where greater transparency and accountability may be needed.

It will also consider whether additional regulatory, statutory or other measures are appropriate.

This distinction is important: the government has announced a review, not a final decision to replace UCPMP 2024 or introduce a specific new penalty regime. Any changes will depend on the committee's recommendations and subsequent government decisions. Press Information Bureau

What Could the Review Mean for Pharmaceutical Companies?

Although no new requirements have been announced through this committee's formation alone, the review provides pharmaceutical companies with a reason to assess their existing compliance systems.

1. Greater scrutiny of promotional practices

The committee is examining how effectively current marketing rules are monitored and enforced.

Depending on its recommendations and any subsequent government action, companies could eventually face stronger oversight of their promotional activities.

For now, businesses should continue following the existing applicable code and other relevant laws.

2. More attention to interactions with healthcare professionals

Pharmaceutical marketing often involves communication between company representatives and doctors, hospitals and other healthcare professionals.

These interactions need to remain consistent with applicable ethical and regulatory requirements.

Companies should ensure that promotional activities, professional engagements, sponsorships and related expenditure are handled transparently and documented appropriately.

3. Stronger internal compliance systems

Pharmaceutical companies can use this period to review their internal procedures, including:

• Approval of promotional materials and product claims.

• Training for medical representatives and sales teams.

• Documentation of professional engagements and marketing expenditure.

• Procedures for receiving and investigating complaints.

• Oversight by designated compliance personnel and ethics officers.

These are practical compliance measures rather than newly announced obligations arising from the committee itself.

4. Potential changes to the regulatory framework

One of the committee's stated responsibilities is to consider whether additional regulatory, statutory or other measures are needed.

If its recommendations are accepted, the government could consider changes to how pharmaceutical marketing rules are implemented or enforced.

The precise nature of any future changes remains uncertain until recommendations and subsequent government decisions are available. Press Information Bureau

What Should Medical Representatives Know?

Medical representatives are an important link between pharmaceutical companies and healthcare professionals. Their work includes communicating authorised product information and supporting professional engagement.

The review makes it particularly useful for field teams and their managers to revisit existing compliance practices.

Medical representatives should:

• Use company-approved and accurate promotional materials.

• Avoid unsupported product claims or misleading comparisons.

• Follow applicable rules concerning gifts, hospitality and other benefits.

• Maintain appropriate records of professional interactions.

• Refer compliance questions to their managers or designated ethics personnel.

The review does not, by itself, establish new duties for medical representatives. Existing requirements continue to apply unless changed through the appropriate process.

What Could This Mean for Doctors and Other Healthcare Professionals?

Ethical pharmaceutical promotion is important because healthcare professionals make decisions that directly affect patient care.

Marketing information should be accurate, relevant and consistent with applicable requirements. Commercial relationships should not compromise independent professional judgement.

The committee's review could lead to recommendations intended to improve transparency and accountability in interactions between pharmaceutical companies and healthcare professionals.

However, the announcement does not establish that doctors or healthcare institutions will immediately face new restrictions. The scope of any future changes will depend on the review and subsequent decisions.

What Should Pharma Businesses Do Now?

Pharmaceutical companies do not need to wait for the committee's report to strengthen their internal compliance practices.

A practical approach is to conduct an internal review of existing procedures.

First, review current compliance policies. Confirm that marketing teams understand UCPMP 2024 and its subsequent amendments, along with other applicable legal requirements.

Second, check documentation. Ensure that records relating to promotional activities, professional engagements and marketing expenditure are accurate and maintained appropriately.

Third, strengthen staff training. Medical representatives, sales managers and marketing teams should understand the difference between legitimate product communication and potentially unethical promotional conduct.

Fourth, maintain an effective complaint process. Employees should know how to raise concerns and how those concerns are handled.

Finally, monitor official announcements. Companies should rely on notifications and guidance from the Department of Pharmaceuticals rather than assuming that proposed reforms have already become mandatory.

These steps can help businesses prepare for possible changes without confusing the announced review with new rules already in force.

What Happens Next?

The committee is expected to examine the existing framework, consult relevant stakeholders and submit its recommendations within two months of its first meeting.

Its work will focus on identifying gaps in monitoring and enforcement, considering ways to improve compliance and assessing whether additional regulatory or statutory measures are warranted.

The next significant development will be the committee's recommendations and the government's response to them.

Until then, UCPMP 2024 remains the operative pharmaceutical marketing code, as confirmed by the Department of Pharmaceuticals. Press Information Bureau

Frequently Asked Questions

1. Has the government announced new pharmaceutical marketing rules?

No new rules were announced in the 23 October 2026 committee announcement. The government has established a committee to review the existing framework and recommend possible improvements.

2. What is UCPMP 2024?

The Uniform Code for Pharmaceutical Marketing Practices 2024 is the framework introduced by the Department of Pharmaceuticals to promote ethical pharmaceutical marketing and govern relevant interactions between companies and healthcare professionals.

3. Who is heading the committee?

Dr. M. Srinivas, Member of NITI Aayog, has been appointed chairperson. Preeti Sudan, former Union Health Secretary, and Dr. Naresh Trehan, CMD of Medanta, are the other members.

4. When will the committee submit its report?

The committee is required to submit its recommendations within two months of its first meeting. The date of that first meeting is needed to establish the exact deadline.

5. Will pharmaceutical companies immediately have to change their marketing practices?

The committee's formation does not itself create new requirements. Companies should continue complying with the existing applicable framework and monitor official announcements for any future changes.

Conclusion

The government's decision to review pharmaceutical marketing practices is an important development for India's pharmaceutical industry.

By examining existing oversight mechanisms and considering potential regulatory improvements, the committee has been tasked with identifying ways to strengthen transparency, accountability and ethical compliance.

For pharmaceutical companies, medical representatives and healthcare professionals, the immediate priority is to continue following existing requirements while keeping track of the review's progress.

The key takeaway is that the regulatory review has begun, but its eventual impact will depend on the recommendations and the government's subsequent decisions.

Official Sources and Further Reading

1. Department of Pharmaceuticals / Press Information Bureau: Department of Pharmaceuticals Constitutes Committee to Review Pharmaceutical Marketing Practices — 23 October 2026

2. Press Information Bureau: Government's explanation of UCPMP 2024 and its implementation framework — 24 July 2026

3. Department of Pharmaceuticals: Uniform Code for Pharmaceutical Marketing Practices

Editorial note: This article is an informational report based on official government announcements available as of 25 October 2026. Potential future regulatory changes are described as possibilities, not confirmed policy decisions.